2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Van Voorhees A, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Journal Of The American Academy Of Dermatology 2020, 83: 96-103. PMID: 32032692, DOI: 10.1016/j.jaad.2020.01.072.Peer-Reviewed Original ResearchConceptsSevere scalp psoriasisNumeric rating scaleItch Numeric Rating ScaleDermatology Life Quality IndexSafety of apremilastScalp psoriasisPhase 3bWeek 16Inadequate response/intolerancePhysician Global Assessment responseCommon adverse eventsPhysician global assessmentPlacebo-controlled studySevere plaque psoriasisDouble-blind studyProportion of patientsLife Quality IndexPruritic areaPlaque psoriasisPrimary endpointSecondary endpointsAdverse eventsMore patientsMild diseasePsoriasis therapy
2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal Of The American Academy Of Dermatology 2017, 76: 1093-1102. PMID: 28291552, DOI: 10.1016/j.jaad.2016.12.014.Peer-Reviewed Original ResearchConceptsABP 501Week 16Psoriasis AreaClinical similaritiesBiosimilar ABP 501Biosimilars of adalimumabSevere plaque psoriasisDouble-blind studySeverity Index scoreTreatment of patientsAntibody incidencePlaque psoriasisSevere psoriasisAdalimumabIndex scoreEquivalence marginPatientsImmunogenicityConfidence intervalsTreatment differencesPercent improvementPsoriasisSame treatmentBaselineMore improvement